Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Researchers discover new connection

How a signaling molecule influences the clinical course of ovarian cancer

    • Gynecology
    • RX
  • 2 minute read

Ovarian cancer is the fifth leading cause of cancer-related death in women, primarily because it is usually detected late, metastasizes early to the abdomen, and available therapeutic agents are usually temporary. New therapeutic approaches are therefore urgently needed. In a research project funded by the Wilhelm Sander Foundation, a Marburg research alliance has now discovered a signaling molecule in the abdominal fluid of affected individuals that is associated with short relapse-free survival and inhibits immune cells in the tumor microenvironment. The underlying molecular changes provide a basis for the development of new therapeutic options.

Ovarian cancer (ovarian carcinoma) is usually detected late, metastasizes to the abdomen early, and the available therapeutic agents are usually not permanently effective. As a result, ovarian cancer remains the fifth leading cause of cancer-related deaths in women, and new targets for improved therapies are urgently needed.

Ovarian carcinomas are also frequently accompanied by malignant abdominal fluid (ascites), which contains tumor-promoting signaling molecules. How these signaling molecules influence the clinical course of ovarian cancer has now been investigated by scientists* led by PD Dr. Sabine Müller-Brüsselbach, working group leader at the Institute of Molecular Biology and Tumor Research (IMT) at Philipps University Marburg, and Dr. Silke Reinartz and Prof. Dr. Uwe Wagner from the Marburg Clinic for Gynecology, Gynecological Endocrinology and Oncology. The goal of the research team’s work was to develop a basis for new prognostic and therapeutic approaches for the treatment of ovarian cancer.

It is now unquestionable that tumors can only grow and metastasize if tumor cells are supported in their activity by surrounding normal cells. These primarily include immune cells and cells of the connective tissue. The resulting tumor microenvironment also influences the clinical course and survival in a crucial way. In ovarian cancer, malignant ascites is a particularly relevant part of the tumor microenvironment (Worzfeld et al., 2017, Front Oncol.; Reinartz et al., 2019, Mol Oncol.). Of particular importance in this context are the scavenger cells of the immune system (macrophages), which are “re-educated” via signal molecules in the tumor microenvironment and as a consequence no longer eliminate the tumor cells but promote their malignancy.

As part of a two-year research project funded by the Wilhelm Sander Foundation, the Marburg researchers made an important discovery: “We were able to link a specific fatty acid (arachidonic acid) in the patients’ ascites to their relapse-free survival (see figure) and also demonstrate that arachidonic acid acts as a signal molecule that inhibits macrophage activity,” says Sabine Müller-Brüsselbach, explaining the most important findings of their investigations. According to this, arachidonic acid enters the macrophages and leads to modifications of specific proteins (phosphorylation), which, among other things, regulate their feeding activity. Of particular importance is that there are pharmacological agents that can prevent such changes. The scientists are currently investigating whether these active substances can also prevent the negative effect of arachidonic acid on macrophages and the course of the disease.

Source: Wilhelm Sander Foundation

Previous Article
  • Telemedicine for SLIT

Useful addition – but not a replacement

  • Allergology and clinical immunology
  • Education
  • General Internal Medicine
  • News
  • Practice Management
  • Prevention and health care
  • RX
View Post
Next Article
  • SARS-CoV-2 vaccination for nursing mothers

Potential benefits outweigh safety concerns

  • Gynecology
  • RX
View Post
You May Also Like
View Post
  • 7 min
  • Plastic surgery and reconstructive microsurgery for DFS

Functional limb preservation between infection control, vascular medicine and resurfacing

    • RX
    • Angiology
    • CME continuing education
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Geriatrics
    • Physical medicine and rehabilitation
    • Surgery
View Post
  • 12 min
  • SURPASS-CVOT

Tirzepatide versus Dulaglutide in T2D with ASCVD

    • RX
    • Cardiology
    • Education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Pharmacology and toxicology
    • Studies
View Post
  • 6 min
  • Secondary prevention after ACS: individually optimized lipid management

Trend towards early combination therapy and new strategies for lowering Lp(a)

    • RX
    • Cardiology
    • Congress Reports
    • General Internal Medicine
    • Studies
View Post
  • 27 min
  • Pediatric Brain Tumors

Psychiatry versus Neuro-Oncology: Diagnostic Pitfalls

    • RX
    • CME continuing education
    • Neurology
    • Oncology
    • Pediatrics
    • Psychiatry and psychotherapy
    • Studies
View Post
  • 13 min
  • What the latest studies on the entire EF spectrum mean for clinical practice

Heart Failure – The 2026 Evidence Update

    • RX
    • Cardiology
    • Education
    • Endocrinology and Diabetology
    • Studies
View Post
  • 5 min
  • Acute ischemic stroke

Alteplase and Tenecteplase Are on the Same Level

    • RX
    • Education
    • Emergency and intensive care medicine
    • Neurology
    • Pharmacology and toxicology
    • Studies
View Post
  • 5 min
  • CKD in People with Type 2 Diabetes: Evidence-Based, Optimized Treatment

SGLT-2 inhibitors and GLP-1 receptor agonists: significant improvement in renal outcomes

    • RX
    • Education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Nephrology
    • Studies
View Post
  • 2 min
  • Wearables: screening via smartwatch?

New study on atrial fibrillation in high-risk patients

    • RX
    • Cardiology
    • Practice Management
    • Prevention and health care
    • Studies
Landingpage Fachinfo Landingpage Button
  • IBD matters

    Zum Thema
Top CME content
  • 1
    Update on Anti-Rheumatic Medications
  • 2
    Psychiatry versus Neuro-Oncology: Diagnostic Pitfalls
  • 3
    Focus on preventive care options
  • 4
    Inflammation as a Treatment Goal in Its Own Right
  • 5
    Personalized Treatment Before a Planned Pregnancy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.